CIBA Vision announces settlement of patent litigation with CooperVision, Inc.

CIBA Vision, the eye care unit of Novartis, has reached a final global patent litigation settlement agreement with CooperVision, Inc. (NYSE: COO) that resolves all current patent infringement lawsuits between the two companies. CIBA Vision has licensed its so called "Nicolson" patents to CooperVision. This will enable both companies to move forward in bringing forth new and improved innovations to meet the needs of eye care professionals and consumers. The Nicolson patents cover high-oxygen-transmissible contact lenses, including CIBA Vision's O2OPTIX(TM), AIR OPTIX(TM) and NIGHT & DAY® silicone hydrogel contact lenses.

In exchange, CooperVision will pay CIBA Vision a royalty on US net sales of its Biofinity® contact lenses until 2014 and on net sales outside of the US until 2016. CIBA Vision also has licensed two patent families from CooperVision related to contact lens designs. Further terms of the agreement are confidential.

This follows a settlement of patent litigation, also involving the Nicolson patents, between CIBA Vision and Bausch & Lomb, reached in 2004, when CIBA Vision and Bausch & Lomb cross-licensed rights to their silicone hydrogel contact lens technologies. As part of the agreement, Bausch & Lomb agreed to pay CIBA Vision a royalty on net US sales of its PureVision(TM) brand contact lenses until 2014 and on net sales outside the US until 2016.

About CIBA Vision
With worldwide headquarters near Atlanta, CIBA Vision is a global leader in research, development and manufacturing of optical products and services, including contact lenses and lens care products. CIBA Vision products are available in more than 70 countries. For more information, visit the CIBA Vision web site at www.cibavision.com.

CIBA Vision is the eye care unit of Novartis, a world leader in offering medicines to protect health, cure disease and improve well-being. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

Most Popular Now

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

Johnson & Johnson statement on COVID-19 vaccin…

The safety and well-being of the people who use our products is our number one priority. We are aware of an extremely rare disorder involving people with blood clots in c...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

GSK and Vir Biotechnology announce EMA review of d…

GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational...

Phase III prevention trial showed subcutaneous adm…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail ...

Amgen successfully completes acquisition of Five P…

Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Pr...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Valneva switches focus to bilateral discussions to…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 vaccine, to the 2...

Patients who are obese or overweight are at risk f…

COVID-19 patients who are overweight or obese are more likely to develop a more severe infection than patients of healthy weight, and they require oxygen and invasive mec...

Massive fragment screen points way to new SARS-CoV…

New research published in Science Advances provides a template for how to develop directly-acting antivirals with novel modes of action, that would combat COVID-19 by sup...